ADMA Biologics Inc $ADMA Shares Bought by Rafferty Asset Management LLC

Rafferty Asset Management LLC lifted its holdings in shares of ADMA Biologics Inc (NASDAQ:ADMA) by 33.9% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 356,151 shares of the biotechnology company’s stock after acquiring an additional 90,223 shares during the period. Rafferty Asset Management LLC owned 0.15% of ADMA Biologics worth $5,221,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Homestead Advisers Corp purchased a new stake in shares of ADMA Biologics in the second quarter valued at about $1,974,000. American Century Companies Inc. grew its holdings in shares of ADMA Biologics by 8.4% during the second quarter. American Century Companies Inc. now owns 4,610,989 shares of the biotechnology company’s stock worth $83,966,000 after buying an additional 358,627 shares during the last quarter. Thrivent Financial for Lutherans increased its position in ADMA Biologics by 24.9% in the 3rd quarter. Thrivent Financial for Lutherans now owns 4,141,840 shares of the biotechnology company’s stock valued at $60,719,000 after acquiring an additional 826,415 shares during the period. Y Intercept Hong Kong Ltd raised its stake in ADMA Biologics by 107.6% during the 2nd quarter. Y Intercept Hong Kong Ltd now owns 74,891 shares of the biotechnology company’s stock valued at $1,364,000 after acquiring an additional 38,809 shares during the last quarter. Finally, Ranger Investment Management L.P. lifted its position in ADMA Biologics by 49.1% during the 2nd quarter. Ranger Investment Management L.P. now owns 2,390,375 shares of the biotechnology company’s stock worth $43,529,000 after acquiring an additional 786,865 shares during the period. 75.68% of the stock is owned by institutional investors and hedge funds.

ADMA Biologics Stock Performance

Shares of ADMA stock opened at $16.58 on Tuesday. The company has a current ratio of 6.71, a quick ratio of 3.74 and a debt-to-equity ratio of 0.16. The stock has a 50 day simple moving average of $17.19 and a 200-day simple moving average of $16.80. The company has a market cap of $3.95 billion, a price-to-earnings ratio of 27.63 and a beta of 0.51. ADMA Biologics Inc has a 12-month low of $13.50 and a 12-month high of $25.67.

ADMA Biologics (NASDAQ:ADMA) last announced its quarterly earnings data on Wednesday, February 25th. The biotechnology company reported $0.20 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.20. The firm had revenue of $139.16 million for the quarter, compared to analyst estimates of $139.80 million. ADMA Biologics had a return on equity of 37.52% and a net margin of 28.80%.ADMA Biologics’s quarterly revenue was up 18.4% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.46 earnings per share. On average, equities analysts forecast that ADMA Biologics Inc will post 0.51 EPS for the current year.

Analyst Ratings Changes

A number of research firms have recently issued reports on ADMA. Wall Street Zen raised ADMA Biologics from a “hold” rating to a “buy” rating in a report on Saturday. Weiss Ratings reissued a “hold (c)” rating on shares of ADMA Biologics in a research note on Tuesday, December 23rd. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $28.50.

About ADMA Biologics

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.